The pharmaceutical industry has taken on parole in developing disease-management programs in collaboration with healthcare providers. One of the most ambitious of these is “Improving Cardiovascular Outcomes for Nova Scotians” (ICONS) - a province-wide study involving multiple stakeholders that intends to measure and improve healthcare for patients at a high risk of a cardiovascular event